Inspire Medical Systems is a medical device company focused on developing innovative solutions to treat obstructive sleep apnea
The company specializes in the design and manufacturing of implantable neurostimulation devices that work to improve airflow during sleep by stimulating the hypoglossal nerve, which helps keep the airway open. Their technology aims to provide an effective alternative for individuals who are unable to tolerate traditional continuous positive airway pressure (CPAP) therapy. Through its pioneering approach, Inspire Medical Systems is committed to enhancing the quality of life for patients with sleep-disordered breathing conditions.
Medical technology company Inspire Medical Systems (NYSEINSP) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24.5% year on year to $239.7 million. The company expects the full year’s revenue to be around $947.5 million, close to analysts’ estimates. Its GAAP profit of $1.15 per share was 54% above analysts’ consensus estimates.
BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.
Inspire Medical Systems recalls Model 3028 IPG due to manufacturing defect causing serious health risks. Learn about the FDA Class I recall implications and patient advisories.
